Risk adjusted net present value: What is the current valuation of Medivir’s Fostroxacitabine Bralpamide Hydrochloride?

Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.

TNF Blockers for IBD Tied to Risk for Immune-Mediated Diseases

Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in

July 23, 2023

Boehringer seeks approval for lung fibrosis drug following Phase III win

Boehringer’s nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B). Image credit: Tada Images / Shutterstock. Boehringer Ingelheim is seeking regulatory approval for nerandomilast after

September 16, 2024

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia – Biotech Investments

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia 22-Jul-2024 / 08:12 CET/CEST Biophytis deploys

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.